drugset / Trial / NCT00853112

A Research Study To Assess The Effectiveness And Safety Of Different Doses Of Oral PF-00489791 In The Treatment Of Adult Patients With Pulmonary Arterial Hypertension

NCT00853112

Phase 2 Terminated 48 enrolled Pfizer
RandomizedParallel-groupTriple-blindTreatment

Summary

Study will assess PF-00489791 efficacy and safety in Pulmonary Arterial Hypertension (PAH)

Timeline

Start
2009-04
Primary completion
2010-07
Completion
2010-07

Drugs

EvaluationDrugModalityDoseRoute
Subject PF-00489791 Small molecule 1 mg Oral
Subject PF-00489791 Small molecule 2 mg Oral
Subject PF-00489791 Small molecule 4 mg Oral
Subject PF-00489791 Small molecule 10 mg Oral
Subject PF-00489791 Small molecule 20 mg Oral
Comparator Sildenafil Unknown 20 mg